Clin Microbiol Infect. 2021 Jun 14:S1198-743X(21)00327-X. doi: 10.1016/j.cmi.2021.06.008. Online ahead of print.
OBJECTIVES: Dexamethasone has become standard of care for severe coronavirus disease 2019 (COVID-19), but its virological impact is poorly understood. The objectives of this work were to characterise the kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) concentration in the upper respiratory tract (URT) and the antibody response in patients with (D+) and without (D-) dexamethasone treatment.
METHODS: Data and biosamples from hospitalised patients with severe COVID-19, enrolled between March 4th and December 11th, 2020, in a prospective observational study, were analysed. SARS-CoV-2 virus concentration in serial URT samples was measured using RT-PCR. SARS-CoV-2-specific Immunoglobulin A and G (IgA and IgG) were measured in serum samples using S1-ELISA.
RESULTS: We compared 101 immunocompetent patients who received dexamethasone according to the inclusion criteria and dosage determined in the RECOVERY trial to 93 immunocompetent patients with comparable disease severity from the first months of the pandemic, who had not been treated with dexamethasone or other glucocorticoids. We found no inter-group differences in virus concentration kinetics, duration of presence of viral loads >106 viral copies/mL (D+: median 17 days (IQR 13-24), D-: 19 days (IQR 13-29)), or time from symptom onset until seroconversion (IgA: D+: median 11.5 days (IQR 11-12), D-: 14 days (IQR 11.5-15.75); IgG: D+: 13 days (IQR 12-14.5), D-: 12 days (IQR 11-15)).
CONCLUSION: Dexamethasone does not appear to lead to a change in virus clearance or a delay in antibody response in immunocompetent patients hospitalised with severe COVID-19.